A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: Report of the southwest oncology group

Archives of Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 9, 2009, Pages 869-874

  Yoo, George H ^a,g   Moon, James ^b   LeBlanc, Michael ^b   Lonardo, Fulvio ^a   Urba, Susan ^c   Kim, Harold ^a   Hanna, Ehab ^d   Tsue, Terry ^e   Valentino, Joseph ^f   Ensley, John ^a   Wolf, Gregory ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVEXIN; CISPLATIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DYSPEPSIA; DYSPNEA; EAR DISEASE; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GRANULOCYTOPENIA; HEARING LOSS; HEARTBURN; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHARYNX CARCINOMA; INFECTION; INSOMNIA; INTESTINE OBSTRUCTION; KIDNEY FAILURE; LARYNX CARCINOMA; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MALE; MOUTH CARCINOMA; MOUTH DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OROCUTANEOUS FISTULA; OROPHARYNX CARCINOMA; PAIN; PERIOPERATIVE PERIOD; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; RASH; SALIVARY GLAND DISEASE; SIDE EFFECT; SKIN EXFOLIATION; SKIN FISTULA; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; VOMITING; WEIGHT REDUCTION; WOUND HEALING; WOUND INFECTION;

ADENOVIRIDAE; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE THERAPY; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNX; INJECTIONS, INTRALESIONAL; LARYNGEAL NEOPLASMS; LARYNX; MALE; MIDDLE AGED; MOUTH; MOUTH NEOPLASMS; NEOPLASM STAGING; OROPHARYNX; PATIENT SELECTION; PERIOPERATIVE CARE; PROBABILITY; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 70349348934     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2009.122     Document Type: Article

References (12)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328(3):184-194.
2. Chomchai JS, Du W, Sarkar FH, et al. Prognostic significance of p53 gene mutations in laryngeal cancer. Laryngoscope. 1999;109(3):455-459. (Pubitemid 29128548)
3. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332(11):712-717.
4. Clayman GL, el-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 1995;55(1):1-6.
5. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res. 1999;5(7):1715-1722. (Pubitemid 29334451)
6. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16(6):2221-2232. (Pubitemid 28265061)
7. Nemunaitis JJ, Clayman G, Hamm J, et al. Tumor response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) [abstract 6057]. J Clin Oncol. 2007;25(18)(suppl):313s.
8. Goodwin WJ, Esser D, Clayman GL, Nemunaitis J, Yver A, Dreiling L. Randomized phase II study of intratumoral injections of two dosing schedules using a replication-deficient adenovirus carrying the p53 gene (Ad5CMV-p53) in patients with recurrent/refractory head and neck cancer [abstract 1717]. Proc Am Soc Clin Oncol. 1999;18:445a.
9. Bier-Laning CM, VanEcho D, Yver A, Dreiling L. A phase II multi-center study of AdCMV-p53 administered intratumorally to patients with recurrent head and neck cancer [abstract 1712]. Proc Am Soc Clin Oncol. 1999;18:431a.
10. Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001; 19(6):1728-1733. (Pubitemid 32230874)
11. Hollon T. Researchers and regulators reflect on first gene therapy death. Nat Med. 2000;6(1):6. (Pubitemid 30048499)
12. Thrasher AJ, Gaspar HB, Baum C, et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature. 2006;443(7109):E5-E6. doi:10.1038/nature05219. (Pubitemid 44435140)